Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 63fludarabine phosphate 52Busulfan 48Cyclosporine 37Antilymphocyte Serum 36Peripheral Blood Stem Cell Transplantation 35Cytarabine 29Filgrastim 28Mycophenolic Acid 27Whole-Body Irradiation 26Radiotherapy 26Melphalan 26Cord Blood Stem Cell Transplantation 24Tacrolimus 23Methotrexate 23Methylprednisolone 21fludarabine 19Etoposide 16Thiotepa 11Granulocyte Colony-Stimulating Factor 11Azacitidine 10Alemtuzumab 9Daunorubicin 8sargramostim 7Idarubicin 7Decitabine 7Biopsy 7Topotecan 6Stem Cell Transplantation 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × paricalcitol × Classical hematology × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡